FA Drug RG2833 Moves from Repligen to BioMarin

BioMarin has purchased from Repligen the rights to experimental compounds for Friedreich’s ataxia and other neurological disorders

by Quest Staff on January 21, 2014 - 2:39pm

Update (Jan. 22, 2014): Read FA: BioMarin To Develop Former Repligen Drugs for an updated version of this story.


Biotechnology company BioMarin has purchased from Repligen Corp. the rights to develop experimental Friedreich’s ataxia (FA) compound RG2833, a histone deacetylase (HDAC) inhibitor that Repligen has been developing with support from MDA, as well as other compounds for FA and for additional neurological disorders.

See a Jan. 21, 2014, press release from Repligen, and BioMarin’s press release of the same date.

No votes yet
MDA cannot respond to questions asked in the comments field. For help with questions, contact your local MDA office or clinic or email publications@mdausa.org. See comment policy